Holen Sie sich die Stockscreener-App
13.08
0.62%
0.08
Handel nachbörslich:
13.02
-0.06
-0.46%
Schlusskurs vom Vortag:
$13.00
Offen:
$13.14
24-Stunden-Volumen:
1.10M
Relative Volume:
0.57
Marktkapitalisierung:
$1.12B
Einnahmen:
$139.71M
Nettoeinkommen (Verlust:
$-209.36M
KGV:
-4.4189
EPS:
-2.96
Netto-Cashflow:
$-160.60M
1W Leistung:
-0.23%
1M Leistung:
-4.04%
6M Leistung:
-44.79%
1J Leistung:
-39.58%
1-Tages-Spanne:
$12.92
$13.21
1-Wochen-Bereich:
$12.06
$13.24
52-Wochen-Spanne:
$12.06
$25.34
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Firmenname
Syndax Pharmaceuticals Inc
Sektor
Branche
Telefon
781-419-1400
Adresse
35 GATEHOUSE DRIVE, WALTHAM, MA
Vergleichen Sie SNDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
13.08 | 1.12B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-10-25 | Eingeleitet | BofA Securities | Buy |
| 2023-10-11 | Eingeleitet | Goldman | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-11 | Eingeleitet | Guggenheim | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2023-01-03 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-04-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-15 | Eingeleitet | Goldman | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-25 | Eingeleitet | Citigroup | Buy |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-05-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Eingeleitet | FBR & Co. | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-10-07 | Eingeleitet | Guggenheim | Buy |
| 2016-03-28 | Eingeleitet | Citigroup | Buy |
| 2016-03-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-03-28 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Syndax Pharmaceuticals (FRA:1T3) Net-Net Working Capital : €3.67 (As of Sep. 2024) - GuruFocus.com
How the (SNDX) price action is used to our Advantage - Stock Traders Daily
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Short Interest Update - MarketBeat
Syndax Pharmaceuticals (FRA:1T3) Price-to-Operating-Cash-Fl - GuruFocus.com
Syndax Pharmaceuticals (FRA:1T3) ROE % Adjusted to Book Val - GuruFocus.com
Assenagon Asset Management S.A. Has $27.29 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Incyte, Syndax get FDA okay for 9 mg, 22 mg Niktimvo vials - MSN
Incyte's and Syndax's Graft Disease Treatment Niktimvo Gets FDA Approval for Vial Sizes - Marketscreener.com
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvotm (axatilimab-csfr) 9 mg and 22 mg Vial Sizes - Lelezard
FDA Approves Niktimvo: Breakthrough Treatment for Chronic GVHD Shows 75% Response Rate - StockTitan
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid AML breakthroughs - Investing.com Nigeria
Syndax Pharmaceuticals (FRA:1T3) Cash From Discontinued Inv - GuruFocus.com
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid AML breakthroughs By Investing.com - Investing.com South Africa
SNDX stock touches 52-week low at $12.38 amid market challenges - Investing.com Nigeria
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 1-Year LowHere's Why - MarketBeat
Syndax Achieves Dual FDA Approvals for Breakthrough Cancer & GVHD Treatments in Major Growth Milestone - StockTitan
Syndax Pharmaceuticals (FRA:1T3) Other Current Receivables : €4.23 Mil (As of Sep. 2024) - GuruFocus.com
Investing in Syndax Pharmaceuticals (NASDAQ:SNDX) five years ago would have delivered you a 53% gain - Yahoo Finance
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com India
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $16.00 Price Target at Scotiabank - MarketBeat
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm - The Eastern Progress Online
Where are the Opportunities in (SNDX) - Stock Traders Daily
Syndax Pharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Jefferies maintains Buy rating on Syndax stock with $43 target By Investing.com - Investing.com Nigeria
Syndax Pharmaceuticals Awards 123,100 Stock Options to New Hires in Growth Initiative - StockTitan
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 4.1%What's Next? - MarketBeat
Stifel Financial Corp Purchases Shares of 16,976 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Price Target at $36.90 - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
SNDX stock touches 52-week low at $12.75 amid market challenges - Investing.com Canada
Syndax Pharmaceuticals (NASDAQ:SNDX) Sets New 1-Year LowWhat's Next? - MarketBeat
Syndax Pharmaceuticals, Inc. Announces Cessation of Catherine Madigan as Chief Medical Officer - Marketscreener.com
Geode Capital Management LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by Geode Capital Management LLC - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 2.6%Should You Sell? - MarketBeat
Barclays PLC Purchases 110,535 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals CMO position eliminated By Investing.com - Investing.com Canada
Syndax Pharmaceuticals CMO position eliminated - Investing.com
Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid FDA approvals - Investing.com
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors - cnhinews.com
Franklin Resources Inc. Has $34.95 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
SNDX stock touches 52-week low at $13.26 amid market challenges - Investing.com Canada
State Street Corp Increases Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Fmr LLC Has $948,000 Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals' SWOT analysis: biotech stock poised for growth amid challenges - Investing.com India
(SNDX) Technical Pivots with Risk Controls - Stock Traders Daily
Finanzdaten der Syndax Pharmaceuticals Inc-Aktie (SNDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):